期刊文献+

环氧化酶2与心血管疾病的关系及其转录调控

Cycloxygenase-2 in Cardiovascular Diseases and its Transcriptional Regulation
下载PDF
导出
摘要 环氧化酶(COX)是花生四烯酸代谢过程中的重要限速酶,其中COX-2是诱导型酶。COX-2及其代谢产物对动脉粥样硬化、高血压和心力衰竭等多种心血管疾病的发生、发展起着重要作用。COX-2的表达受多种转录因子调控,包括核因子κB、C/EBP、激活蛋白1和丝裂原活化蛋白激酶等。本文综述了COX-2与心血管疾病之间的关系、COX-2表达的转录调控及其影响因素。 Cyclooxygenase (COX) is a key enzyme in the metabolic process of arachidonic acid. COX-2 and its metabolic product play a key role in the occurrence and development of cardiovascular disease such as artherosclerosis,hypertension and congestive heart failure and etc. COX-2 is inducible by diverse factors such as transactivators including NF-κB, C/EBP, AP-1, MAPKs, and etc. This article reviewed the relationship between COX-2 and cardiovascular diseases and the factors associated with COX-2 transcriptional regulation.
出处 《医学综述》 2008年第18期2721-2724,共4页 Medical Recapitulate
基金 莱菔硫烷对血管内皮细胞的保护作用及机理研究(30571558)
关键词 环氧化酶 心血管疾病 转录调控 Cyclooxygenase Cardiovascular disease Transcriptional control
  • 相关文献

参考文献24

  • 1MeAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX) -2 :the human pharmacology of a selective inhibitor of COX-2 [ J]. Proc Natl Acad Sci USA, 1999,96 ( 1 ) :272-277.
  • 2Song YG, Kwon HM, Kim JM, et al. Serologic and histopathologic study of ehlamydia pneumoniae infection in atherosclerosis : a possible pathogenetic mechanismof atherosclerosis induced by chlamydia pneumoniae[ J]. Yonsei Med J ,2000,41 (3) :319-327.
  • 3Belton O, Byrne D, Kearney D, et all Cyclooxygenase-1 and-2-dependent prostacyclin formation in patients with atherosclerosls[ J]. Circulation ,2000,102 ( 8 ) ::840-845.
  • 4Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice[ J]. Circulation ,2002,105 ( 15 ) : 1816-1823.
  • 5Linton MF, Fazio S. Cyclooxygenase 2 and atherosclerosis[ J]. Curr Opin Lipidol,2002,13 (5) :497-504.
  • 6Hennan JK, Huang J, Barrett T, et al. Effects of selective cyclooxygenase-2 inhibition on vascular response and thrombosis in canine coronary arteries[ J]. Circulation ,2001,104 (7) :820-825.
  • 7Delgado RM 3rd, Nawar MA, Zewail AM, et al. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a routine model of doxorubicin-induced heart failure[ J]. Circulation ,2004,109 ( 11 ) : 1428-1433.
  • 8Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors [ J ]. JAMA, 2001,286 (8) :954-959.
  • 9LaPointe MC, Mendez M, Leung A, et al. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse [ J ]. Am J Physiol Heart Circ Physiol, 2004,286 ( 4 ) : H1416-1424.
  • 10Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2 : a pharmacological target for the prevention of cancer[ J]. Lancet Oncol ,2001,2 (9) :544-551.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部